newsfilter
← Latest News
Business Wire·

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully